Global Pancreatic Cancer Market to Develop Swiftly by 2018 Owing to Increasing Incidence of Pancreatic Cancer in U.S.

Albany, NY -- (SBWIRE) -- 12/31/2015 -- A new report from Transparency Market Research, titled "Pancreatic Cancer Market - Global Industry Analysis, Size, Share, Trends, Analysis, Growth And Forecasts 2012 - 2018', states that the global pancreatic cancer market is expected to expand rapidly due to factors such as the increasing incidence of pancreatic cancer in the U.S. and advancements in pancreatic cancer treatment.

Pancreatic cancer is triggered by unrestrained growth of cells in the pancreas. This uncontrolled, abnormal growth of cells results in the development of lumps of tissues, commonly termed as tumors. Development of tumors affects the normal functioning of the pancreas. There has been an increase in the incidence of pancreatic cancer in the U.S. over the past few years. Pancreatic cancer has been a major challenge for residents of the United States, as every year, around 30,000 people are diagnosed with this medical condition.

The United States has the highest number of people diagnosed with pancreatic cancer across the globe. One of the greatest challenges for the leading companies in the pancreatic cancer market is to introduce advanced therapies to treat pancreatic cancer. Considering the aggressive nature of this cancer, the treatments and therapies that are currently available in the global market are not sufficient to return adequate results. This is another important barrier that needs to be addressed by the leading players in the coming few years.

Technologies and therapies to diagnose and treat pancreatic cancer in a timely manner are not yet fully developed, thus, people suffering from this aggressive disease are usually diagnosed at a very advanced stage. This results in a high mortality rate related to pancreatic cancer. As per recent estimates, only around 12% to 15% of people are diagnosed with pancreatic cancer at its early stage and receive suitable treatments on time. Drugs, surgical procedures, and chemotherapy are the common ways to treat pancreatic cancer. Starting at stage I, pancreatic cancer can advance till stage IV. Pancreatic cancer, when detected at stage I and stage II, can be surgically removed and treated. People diagnosed with pancreatic cancer at later stages, i.e. stage III and stage IV, have less chances of survival.

The global pancreatic cancer market is segmented on the basis of whether the cancer affects the exocrine or endocrine functions of the pancreas. Adenocarcinomas constitute around 95% of exocrine pancreatic cancers and are one of the most common types of pancreatic cancer. Giant cell carcinomas, adenosquamous carcinomas, and squamous cell carcinomas are some of the other common types of pancreatic cancers that affect endocrine functions. The global pancreatic cancer market is led by Gemzar, developed by Eli Lilly. Gemzar ranks among the highly advanced kinds of drug therapies, commonly recommended for treating advanced stage cancer, i.e. stage III and stage IV.

Abraxane by Celgene is also a popular therapeutic drug and was first introduced in the United States in 2013 and in Europe in 2014. Abraxane was the first ever drug approved for treating pancreatic cancer and is predicted to compete with other treatments and drugs in the years to come.

About Transparency Market Research (TMR)
Transparency Market Research (TMR) is a U.S.-based provider of syndicated research, customized research, and consulting services. TMR's global and regional market intelligence coverage includes industries such as pharmaceutical, chemicals and materials, technology and media, food and beverages, and consumer goods, among others. Each TMR research report provides clients with a 360-degree view of the market with statistical forecasts, competitive landscape, detailed segmentation, key trends, and strategic recommendations.